A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Sponsor
Eli Lilly and Company
Study ID
NCT05086445
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3502970 — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

Key Dates

First listed
Oct 21, 2021
Start date
Nov 12, 2021
Status verified
Jun 2026
Primary completion
Sep 5, 2022
Completion
Sep 5, 2022

Study Design

Enrollment
62 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3502970 (Part A)
    Participants received single doses of LY3502970 administered orally.
  • Experimental: LY3502970 (Part B)
    Participants received multiple doses of LY3502970 administered orally.
  • Placebo Comparator: Placebo (Part A)
    Participants received placebo administered orally.
  • Placebo Comparator: Placebo (Part B)
    Participants received placebo administered orally.

Primary Outcome Measure

Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline Through Follow-Up (Up To Week 15) ]

Related coverage on Hipa.ai

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies